FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea

Bolest nealkoholne masne jetre kao metabolička posledica opstruktivne apneje u snu

Thumbnail
2020
Non-alcoholic_fatty_liver_pub_2020.pdf (411.5Kb)
Authors
Ninić, Ana
Zdravković, Marija
Radosavljević, Vojislav
Gardijan, Vera
Memon, Lidija
Vekić, Jelena
Spasojević-Kalimanovska, Vesna
Article (Published version)
Metadata
Show full item record
Abstract
Obstructive sleep apnea (OSA) as a worldwide prevalent condition carries risk for cardiovascular and metabolic diseases, ultimately increasingoverall mortality rates. Non-alcoholic fatty liver disease (NAFLD) can be considered as the primary metabolic disease, but also as a coexisting OSA comorbidity. Although prevalence of NAFLD covers quarter of world population, it increases with OSA presence. It can be speculated that chronic intermittent hypoxia (CIH) and sympathetic nervous system overactivity are involved in NAFLD pathogenesis and progression from simple steatosis throughsteatohepatitis to fibrosis. CIH provides the environment for liveroxidative stress, inflammation and increases the expression of genes involved in cholesterol and fatty acids synthesis. Catecholamines increase β-oxidation in liver and release free fatty acids from adipose tissue in plasma which inhibit insulin effects. Obesity and insulin resistance as ...key playersin NAFLD development and advancement, deepen vicious circle of oxidative stress, inflammation and dyslipidemia. If not treated, OSA in NAFLD patients has been associated with inflammation, hepatocytes’ necrosis, and fibrosis. Continuous positive airway pressure (CPAP) represents gold standard for OSA therapy, allowing the unimpeded air passage through upper parts of respiratory system. However, it has been demonstrated that CPAP therapyhave beneficial effects on cardiometabolic outcomes and slowliver degeneration

Opstruktivna apneja u snu (OSA) kao oboljenje prevalentno u svetu nosi rizik za nastanak kardiovaskularnih i metaboličkih bolesti, povećavajući ukupnu smrtnost. Bolest nealkoholne masne jetre (eng. non-alcoholic fatty liver disease -NAFLD) se može smatrati primarnom metaboličkom bolešću, ali kao i komorbiditet OSA. Iako prevalenca NAFLD obuhvata četvrtinu svetske populacije, ona se povećava sa prisustvom OSA. Pretpostavlja se da su hronična intermitentna hipoksija (eng. chronic intermittent hypoxia -CIH) i prekomerna aktivnost simpatičkog nervnog sistema uključeni u patogenezu NAFLD i progresiju od steatoze preko steatohepatitisa do fibroze. U jetri CIH stvara uslove za oksidativni stres, inflamaciju i povećava ekspresiju gena koji učestvuju u sintezi holesterola i masnih kiselina. Kateholamini stimulišu b-oksidaciju masnih kiselina u jetri i oslobađaju slobodne masne kiseline iz masnog tkiva u plazmu, koje inhibiraju dejstva insulina. Gojaznost i insulinska rezistencija kao ključni fa...ktori u razvoju i napredovanju NAFLD produbljuju začarani krug oksidativnog stresa, inflamacije i dislipidemije. Ako se ne leči, OSA kod pacijenata sa NAFLD je povezana sa inflamacijom, nekrozom hepatocita i fibrozom. Kontinuirani pozitivni pritisak vazduha (eng. continuous positive airway pressure -CPAP) predstavlja zlatni standard u terapiji OSA, koji omogućava neometani prolaz vazduha kroz gornje delove respiratornog sistema. Međutim, CPAP terapija je pokazala da ima povoljne efekte na kardiometaboličke ishode i da usporava degeneraciju jetre.

Keywords:
obstructive sleep apnea / chronic intermittent hypoxia / non-alcoholic fatty liver disease / fibrosis / opstruktivna apneja u snu / hronična intermitentna hipoksija / bolest nealkoholne masne jetre / fibroza
Source:
Arhiv za farmaciju, 2020, 70, 6, 319-331
Publisher:
  • Pharmaceutical Association of Serbia
Funding / projects:
  • Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 200161 (University of Belgrade, Faculty of Pharmacy) (RS-200161)

DOI: 10.5937/arhfarm70-27586

ISSN: 0004-1963

Scopus: 2-s2.0-85100153562
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3769
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Ninić, Ana
AU  - Zdravković, Marija
AU  - Radosavljević, Vojislav
AU  - Gardijan, Vera
AU  - Memon, Lidija
AU  - Vekić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3769
AB  - Obstructive  sleep  apnea  (OSA)  as  a  worldwide  prevalent  condition  carries  risk  for cardiovascular  and  metabolic  diseases,  ultimately  increasingoverall  mortality  rates.  Non-alcoholic fatty liver disease  (NAFLD) can be considered as the primary metabolic  disease,  but also as a coexisting OSA comorbidity. Although prevalence of NAFLD covers quarter of world population, it increases with OSA presence. It can be speculated that chronic intermittent hypoxia (CIH)  and  sympathetic  nervous  system  overactivity  are  involved  in  NAFLD  pathogenesis  and progression   from   simple   steatosis throughsteatohepatitis   to   fibrosis.   CIH   provides   the environment  for  liveroxidative  stress,  inflammation  and  increases  the  expression  of  genes involved in cholesterol and fatty acids synthesis. Catecholamines increase β-oxidation in liver and release free fatty acids from adipose tissue in plasma which inhibit insulin effects. Obesity and insulin resistance as key playersin NAFLD development and advancement, deepen vicious circle of oxidative stress, inflammation and dyslipidemia. If not treated, OSA in NAFLD patients has been  associated  with inflammation, hepatocytes’ necrosis,  and  fibrosis.  Continuous  positive airway pressure (CPAP) represents gold standard for OSA therapy, allowing the unimpeded air passage through upper parts of respiratory system. However, it has been demonstrated that CPAP therapyhave beneficial effects on cardiometabolic outcomes and slowliver degeneration
AB  - Opstruktivna apneja u snu (OSA) kao oboljenje prevalentno u svetu nosi rizik za nastanak kardiovaskularnih i metaboličkih bolesti, povećavajući ukupnu smrtnost. Bolest nealkoholne masne jetre (eng. non-alcoholic fatty liver disease -NAFLD) se može smatrati primarnom metaboličkom bolešću, ali kao i komorbiditet OSA. Iako prevalenca NAFLD obuhvata četvrtinu svetske populacije, ona se povećava sa prisustvom OSA. Pretpostavlja se da su hronična intermitentna hipoksija (eng. chronic intermittent hypoxia -CIH) i prekomerna aktivnost simpatičkog nervnog sistema uključeni u patogenezu NAFLD i progresiju od steatoze preko steatohepatitisa do fibroze. U jetri CIH stvara uslove za oksidativni stres, inflamaciju i povećava ekspresiju gena koji učestvuju u sintezi holesterola i masnih kiselina. Kateholamini stimulišu b-oksidaciju masnih kiselina u jetri i oslobađaju slobodne masne kiseline iz masnog tkiva u plazmu, koje inhibiraju dejstva insulina. Gojaznost i insulinska rezistencija kao ključni faktori u razvoju i napredovanju NAFLD produbljuju začarani krug oksidativnog stresa, inflamacije i dislipidemije. Ako se ne leči, OSA kod pacijenata sa NAFLD je povezana sa inflamacijom, nekrozom hepatocita i fibrozom. Kontinuirani pozitivni pritisak vazduha (eng. continuous positive airway pressure -CPAP) predstavlja zlatni standard u terapiji OSA, koji omogućava neometani prolaz vazduha kroz gornje delove respiratornog sistema. Međutim, CPAP terapija je pokazala da ima povoljne efekte na kardiometaboličke ishode i da usporava degeneraciju jetre.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea
T1  - Bolest nealkoholne masne jetre kao metabolička posledica opstruktivne apneje u snu
VL  - 70
IS  - 6
SP  - 319
EP  - 331
DO  - 10.5937/arhfarm70-27586
ER  - 
@article{
author = "Ninić, Ana and Zdravković, Marija and Radosavljević, Vojislav and Gardijan, Vera and Memon, Lidija and Vekić, Jelena and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Obstructive  sleep  apnea  (OSA)  as  a  worldwide  prevalent  condition  carries  risk  for cardiovascular  and  metabolic  diseases,  ultimately  increasingoverall  mortality  rates.  Non-alcoholic fatty liver disease  (NAFLD) can be considered as the primary metabolic  disease,  but also as a coexisting OSA comorbidity. Although prevalence of NAFLD covers quarter of world population, it increases with OSA presence. It can be speculated that chronic intermittent hypoxia (CIH)  and  sympathetic  nervous  system  overactivity  are  involved  in  NAFLD  pathogenesis  and progression   from   simple   steatosis throughsteatohepatitis   to   fibrosis.   CIH   provides   the environment  for  liveroxidative  stress,  inflammation  and  increases  the  expression  of  genes involved in cholesterol and fatty acids synthesis. Catecholamines increase β-oxidation in liver and release free fatty acids from adipose tissue in plasma which inhibit insulin effects. Obesity and insulin resistance as key playersin NAFLD development and advancement, deepen vicious circle of oxidative stress, inflammation and dyslipidemia. If not treated, OSA in NAFLD patients has been  associated  with inflammation, hepatocytes’ necrosis,  and  fibrosis.  Continuous  positive airway pressure (CPAP) represents gold standard for OSA therapy, allowing the unimpeded air passage through upper parts of respiratory system. However, it has been demonstrated that CPAP therapyhave beneficial effects on cardiometabolic outcomes and slowliver degeneration, Opstruktivna apneja u snu (OSA) kao oboljenje prevalentno u svetu nosi rizik za nastanak kardiovaskularnih i metaboličkih bolesti, povećavajući ukupnu smrtnost. Bolest nealkoholne masne jetre (eng. non-alcoholic fatty liver disease -NAFLD) se može smatrati primarnom metaboličkom bolešću, ali kao i komorbiditet OSA. Iako prevalenca NAFLD obuhvata četvrtinu svetske populacije, ona se povećava sa prisustvom OSA. Pretpostavlja se da su hronična intermitentna hipoksija (eng. chronic intermittent hypoxia -CIH) i prekomerna aktivnost simpatičkog nervnog sistema uključeni u patogenezu NAFLD i progresiju od steatoze preko steatohepatitisa do fibroze. U jetri CIH stvara uslove za oksidativni stres, inflamaciju i povećava ekspresiju gena koji učestvuju u sintezi holesterola i masnih kiselina. Kateholamini stimulišu b-oksidaciju masnih kiselina u jetri i oslobađaju slobodne masne kiseline iz masnog tkiva u plazmu, koje inhibiraju dejstva insulina. Gojaznost i insulinska rezistencija kao ključni faktori u razvoju i napredovanju NAFLD produbljuju začarani krug oksidativnog stresa, inflamacije i dislipidemije. Ako se ne leči, OSA kod pacijenata sa NAFLD je povezana sa inflamacijom, nekrozom hepatocita i fibrozom. Kontinuirani pozitivni pritisak vazduha (eng. continuous positive airway pressure -CPAP) predstavlja zlatni standard u terapiji OSA, koji omogućava neometani prolaz vazduha kroz gornje delove respiratornog sistema. Međutim, CPAP terapija je pokazala da ima povoljne efekte na kardiometaboličke ishode i da usporava degeneraciju jetre.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea, Bolest nealkoholne masne jetre kao metabolička posledica opstruktivne apneje u snu",
volume = "70",
number = "6",
pages = "319-331",
doi = "10.5937/arhfarm70-27586"
}
Ninić, A., Zdravković, M., Radosavljević, V., Gardijan, V., Memon, L., Vekić, J.,& Spasojević-Kalimanovska, V.. (2020). Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 70(6), 319-331.
https://doi.org/10.5937/arhfarm70-27586
Ninić A, Zdravković M, Radosavljević V, Gardijan V, Memon L, Vekić J, Spasojević-Kalimanovska V. Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea. in Arhiv za farmaciju. 2020;70(6):319-331.
doi:10.5937/arhfarm70-27586 .
Ninić, Ana, Zdravković, Marija, Radosavljević, Vojislav, Gardijan, Vera, Memon, Lidija, Vekić, Jelena, Spasojević-Kalimanovska, Vesna, "Non-alcoholic fatty liver disease as metabolic consequence of obstructive sleep apnea" in Arhiv za farmaciju, 70, no. 6 (2020):319-331,
https://doi.org/10.5937/arhfarm70-27586 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB